Menu
← Oncology Approval Tracker
FDA DECISION ·
Decnupaz
pivekimab sunirine-pvzy · AbbVie
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
LAMPGEN ANALYSIS
Why it matters
A CD123-directed antibody-drug conjugate adds a treatment option for an ultra-rare blood cancer. The untreated and relapsed or refractory CADENZA cohorts should be reported separately.
What research teams should watch
Rapid pathology confirmation and referral matter when a rare diagnosis may be missed. Align disease assessment and record whether treatment is intended as a bridge to transplant.
PRIMARY RECORDS